Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ARDX
stocks logo

ARDX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
119.26M
+2.7%
0.014
-31.6%
Estimates Revision
The market is revising Upward the revenue expectations for Ardelyx, Inc. (ARDX) for FY2025, with the revenue forecasts being adjusted by 4.45% over the past three months. During the same period, the stock price has changed by -9.20%.
Revenue Estimates for FY2025
Revise Upward
up Image
+4.45%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-33.66%
In Past 3 Month
Stock Price
Go Down
down Image
-9.20%
In Past 3 Month
Wall Street analysts forecast ARDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARDX is 11.50 USD with a low forecast of 10.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast ARDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARDX is 11.50 USD with a low forecast of 10.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.920
sliders
Low
10.00
Averages
11.50
High
14.00
Current: 5.920
sliders
Low
10.00
Averages
11.50
High
14.00
Piper Sandler
Neutral
maintain
$9 -> $10
2025-11-04
Reason
Piper Sandler
Price Target
$9 -> $10
2025-11-04
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Ardelyx to $10 from $9 and keeps a Neutral rating on the shares. Total revenue nicely beat consensus by over $11M, and notably, Ibsrela exceeded company-provided consensus by $7M, which the firm thinks highlights the continued strength of Ardelyx's sales force and patient access pathways. Overall, Piper looks to more formal evidence of Xphozah's near- and immediate-term outlook, which would leave the firm more constructive on shares.
Citi
Buy
upgrade
$10 -> $11
2025-11-03
Reason
Citi
Price Target
$10 -> $11
2025-11-03
upgrade
Buy
Reason
Citi raised the firm's price target on Ardelyx to $11 from $10 and keeps a Buy rating on the shares.
TD Cowen
Buy
maintain
$9 -> $10
2025-10-31
Reason
TD Cowen
Price Target
$9 -> $10
2025-10-31
maintain
Buy
Reason
TD Cowen raised the firm's price target on Ardelyx to $10 from $9 and keeps a Buy rating on the shares. The firm said the reported Q3 product sales of $105.5MM, above the consensus of $98.2MME. Ibsrela sales were $78.2MM versus $70.9MME consensus, and given strength, the company has again raised FY25 Ibsrela sales guidance to $270-275MM.
Raymond James
Christopher Raymond
Outperform -> Strong Buy
upgrade
$12 -> $14
2025-09-02
Reason
Raymond James
Christopher Raymond
Price Target
$12 -> $14
2025-09-02
upgrade
Outperform -> Strong Buy
Reason
Raymond James analyst Christopher Raymond upgraded Ardelyx to Strong Buy from Outperform with a price target of $14, up from $12, after assuming coverage the name. The firm views Ardelyx as a strong commercial execution story that is trading at historically discounted valuation. The stock could break out of its range-bound trading pattern under the new management team as Xphozah growth picks up, the analyst tells investors in a research note.
Piper Sandler
Neutral
maintain
$8 -> $9
2025-08-06
Reason
Piper Sandler
Price Target
$8 -> $9
2025-08-06
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Ardelyx to $9 from $8 and keeps a Neutral rating on the shares. The firm is incrementally positive on the name following Q2 2025 reporting. That said, with management still not committing to Xphozah guidance this year but continuing to guide to $750M in peak U.S. sales before patent expiry, the firm continues to look for a better sense of uptake and the near- and immediate-term outlook for this drug before getting more constructive on the name.
Raymond James
Outperform
maintain
$11 -> $12
2025-08-05
Reason
Raymond James
Price Target
$11 -> $12
2025-08-05
maintain
Outperform
Reason
Raymond James raised the firm's price target on Ardelyx to $12 from $11 and keeps an Outperform rating on the shares. The substantial consensus beat and return to quarter over quarter growth suggests unfavorable Q1 seasonality is likely to remain prominent in out years, but also de-risks Ibserla guidance as well as the peak sales target for Xphozah, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Ardelyx Inc (ARDX.O) is 135.47, compared to its 5-year average forward P/E of 11.96. For a more detailed relative valuation and DCF analysis to assess Ardelyx Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
11.96
Current PE
135.47
Overvalued PE
234.32
Undervalued PE
-210.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-14.41
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
24.86
Undervalued EV/EBITDA
-53.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
24.44
Current PS
0.00
Overvalued PS
76.83
Undervalued PS
-27.96
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 129.11% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ARDX News & Events

Events Timeline

(ET)
2025-10-30
16:21:41
Ardelyx Announces Q3 Earnings Per Share of 0c, Falling Short of Consensus Estimate of 7c
select
2025-10-28 (ET)
2025-10-28
08:27:51
Ardelyx showcases IBSRELA findings at the ACG annual scientific conference.
select
2025-10-13 (ET)
2025-10-13
08:34:41
Ardelyx Names Hohenleitner as CFO
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-28NASDAQ.COM
Ardelyx (ARDX) Third Quarter 2025 Earnings Call Summary
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
9.5
11-04Benzinga
Insperity Reports Disappointing Q3 Results, Alongside IAC, Archer-Daniels-Midland, and Other Major Stocks Declining in Tuesday's Pre-Market Trading

  • U.S. Stock Market Trends: U.S. stock futures are down, with the Dow futures dropping over 300 points, indicating a bearish market sentiment.

  • Insperity Inc Financial Results: Insperity Inc's shares fell 31.3% in pre-market trading after reporting a quarterly loss of 20 cents per share, missing analyst expectations.

  • Other Notable Stock Movements: Several companies, including Sarepta Therapeutics and Jeld-Wen, experienced significant declines in pre-market trading due to disappointing financial results and lowered guidance.

  • General Market Sentiment: The overall market is reacting negatively to various companies' earnings reports, leading to widespread declines in stock prices across multiple sectors.

[object Object]
Preview
2.0
11-04Benzinga
Upwork Shares Surge Over 22%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Upwork's Strong Performance: Upwork Inc's shares surged 22.2% in pre-market trading after reporting third-quarter earnings of 36 cents per share, exceeding estimates, and raising its FY25 guidance.

  • Other Notable Gainers: Several stocks saw significant pre-market gains, including PTL Ltd (+67.4%), MSP Recovery Inc (+56.9%), and Denny’s Corp (+49.2%) following positive financial announcements.

  • Major Losers: Sarepta Therapeutics Inc experienced a sharp decline of 38.7% after disappointing third-quarter results, while Insperity Inc fell 31.3% due to worse-than-expected financial performance and lowered guidance.

  • Market Overview: The pre-market trading session showed a mix of gains and losses, with notable movements in various stocks, reflecting the impact of recent earnings reports and guidance updates.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Ardelyx Inc (ARDX) stock price today?

The current price of ARDX is 5.92 USD — it has increased 2.6 % in the last trading day.

arrow icon

What is Ardelyx Inc (ARDX)'s business?

Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing first-in-class medicines. The Company has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.

arrow icon

What is the price predicton of ARDX Stock?

Wall Street analysts forecast ARDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARDX is 11.50 USD with a low forecast of 10.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Ardelyx Inc (ARDX)'s revenue for the last quarter?

Ardelyx Inc revenue for the last quarter amounts to 110.33M USD, increased 12.30 % YoY.

arrow icon

What is Ardelyx Inc (ARDX)'s earnings per share (EPS) for the last quarter?

Ardelyx Inc. EPS for the last quarter amounts to -0.00 USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Ardelyx Inc (ARDX)'s fundamentals?

The market is revising Upward the revenue expectations for Ardelyx, Inc. (ARDX) for FY2025, with the revenue forecasts being adjusted by 4.45% over the past three months. During the same period, the stock price has changed by -9.20%.
arrow icon

How many employees does Ardelyx Inc (ARDX). have?

Ardelyx Inc (ARDX) has 395 emplpoyees as of December 05 2025.

arrow icon

What is Ardelyx Inc (ARDX) market cap?

Today ARDX has the market capitalization of 1.44B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free